SREBP-1c and TFE3, energy transcription factors that regulate hepatic insulin signaling

被引:38
作者
Shimano, Hitoshi
机构
[1] Univ Tsukuba, Dept Internal Med Endocrinol & Metab, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 3058575, Japan
[2] Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058575, Japan
来源
JOURNAL OF MOLECULAR MEDICINE-JMM | 2007年 / 85卷 / 05期
关键词
insulin signaling; lipogenesis; metabolic syndrome;
D O I
10.1007/s00109-007-0158-5
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Genes involved in carbohydrate and lipid metabolism are nutritionally regulated at the transcriptional level in a coordinated fashion. SREBP-1c is a bHLH transcription factor that controls lipogenesis and is induced during overnutrition to facilitate the conversion of glucose to fatty acids and triglycerides for the storage of the excess energy. Uncontrolled activation of nuclear SREBP-1c in the liver can cause hepatosteatosis, hypertriglyceridemia, and hepatic insulin resistance due to direct suppression of insulin signaling pathways, precipitating development of metabolic syndrome. Conversely, TFE3 is a novel bHLH transcription factor that strongly activates various insulin signaling molecules, protecting against the development of insulin resistance and the metabolic syndrome. Regulation of IRS-2 is the primary site where TFE3 in synergy with Foxo1, and SREBP-1c converge. Taken together, TFE3/Foxo1 and SREBP-1c reciprocally regulate IRS-2 expression and insulin sensitivity in the liver. This scenario provides a mechanistic explanation for the physiological link between glucose and lipid metabolism such as physiological switching of glycogen synthesis to lipogenesis. In addition, these two transcription factors may ultimately contribute to pathophysiological effects of overnutrition leading to the development of the metabolic syndrome and diabetes. In this review, I will discuss roles of SREBP-1c and TFE3 in homeostasis of energy metabolism and in metabolic disturbances, focusing on hepatic insulin sensitivity.
引用
收藏
页码:437 / 444
页数:8
相关论文
共 46 条
[1]   Promoter analysis of the mouse sterol regulatory element-binding protein-1c gene [J].
Amemiya-Kudo, M ;
Shimano, H ;
Yoshikawa, T ;
Yahagi, N ;
Hasty, AH ;
Okazaki, H ;
Tamura, Y ;
Shionoiri, F ;
Iizuka, Y ;
Ohashi, K ;
Osuga, J ;
Harada, K ;
Gotoda, T ;
Sato, R ;
Kimura, S ;
Ishibashi, S ;
Yamada, N .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (40) :31078-31085
[2]   Novel concepts in insulin regulation of hepatic gluconeogenesis [J].
Barthel, A ;
Schmoll, D .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2003, 285 (04) :E685-E692
[3]   TFE3 - A HELIX LOOP HELIX PROTEIN THAT ACTIVATES TRANSCRIPTION THROUGH THE IMMUNOGLOBULIN ENHANCER MU-E3 MOTIF [J].
BECKMANN, H ;
SU, LK ;
KADESCH, T .
GENES & DEVELOPMENT, 1990, 4 (02) :167-179
[4]   How do we tell the workers? The socioeconomic foundations of work and vocational education [J].
Brown, M .
ADULT EDUCATION QUARTERLY, 2003, 54 (01) :75-77
[5]   The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor [J].
Brown, MS ;
Goldstein, JL .
CELL, 1997, 89 (03) :331-340
[6]   A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood [J].
Brown, MS ;
Goldstein, JL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (20) :11041-11048
[7]  
Foretz M, 1999, MOL CELL BIOL, V19, P3760
[8]   Sterol regulatory element-binding protein-1 is regulated by glucose at the transcriptional level [J].
Hasty, AH ;
Shimano, H ;
Yahagi, N ;
Amemiya-Kudo, M ;
Perrey, S ;
Yoshikawa, T ;
Osuga, J ;
Okazaki, H ;
Tamura, Y ;
Iizuka, Y ;
Shionoiri, F ;
Ohashi, K ;
Harada, K ;
Gotoda, T ;
Nagai, R ;
Ishibashi, S ;
Yamada, N .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (40) :31069-31077
[9]  
HASTY AH, 2001, J BIOL CHEM
[10]   Disruption of LDL receptor gene in transgenic SREBP-1a mice unmasks hyperlipidemia resulting from production of lipid-rich VLDL [J].
Horton, JD ;
Shimano, H ;
Hamilton, RL ;
Brown, MS ;
Goldstein, JL .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (07) :1067-1076